Our data demonstrated a significant reduction in Bax and Bak activation in CD69Pos CLL cells as compared with their CD69Neg counterparts in multiple patient samples incubated with inhibitors of Bcl-2 (VEN: 12.5, 25, 50, 100 nM), Mcl-1 (S63845: 0.61, 0.91, 1.35, 2.05 μM), or Bcl-xL (A1155463: 4, 8, 16, 32 μM) (Figure 1, A–C, and Supplemental Table 2). This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.